Deutsche Bank Questions Long-Term Efficacy Of Sarepta's Eteplirsen Following Trial News

By: via Benzinga
Shares of Sarepta Therapeurics (NASDAQ: SRPT) plummeted 28.2 percent Thursday morning following the long-term outcomes from the Phase ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.